Clinical Trials: Overview
Drug Regulation
Preclinical Development: Overview
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Products: Biologics, Biosimilars and Interchangeables
FDA Approved Drugs: Changes to Approved Drugs
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jul 9, 2026

In Vivo Alkaline Comet Assay and Enzyme-modified Alkaline Comet Assay for Measuring DNA Strand Breaks and Oxidative DNA Damage in Rat Liver
Published on: May 4, 2016
Charles Wu1, Su-Lin Lee2, Cassandra Taylor1
1Botanical Review Team, Science Staff, Immediate Office, Office of Pharmaceutical Quality , Center for Drug Evaluation and Research, Food and Drug Administration , 10903 New Hampshire Avenue , Silver Spring , Maryland 20993 , United States.
Botanical drug development in the U.S. faces challenges despite numerous investigational new drug (IND) applications. Analysis of INDs reveals diverse raw materials and therapeutic areas, highlighting the need for regulatory guidance.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: